| Literature DB >> 24684721 |
Debbie A E Hendrickx, Karianne G Schuurman, Michael van Draanen, Jörg Hamann, Inge Huitinga1.
Abstract
BACKGROUND: The pathological hallmark of multiple sclerosis (MS) is myelin phagocytosis. It remains unclear why microglia and macrophages demyelinate axons in MS, but previously found or yet-unknown changes in the myelin of MS patients could contribute to this process. We therefore studied whether myelin from normal-appearing white matter (NAWM) of MS donors is phagocytosed more efficiently than myelin from control donors.Entities:
Mesh:
Substances:
Year: 2014 PMID: 24684721 PMCID: PMC4108133 DOI: 10.1186/1742-2094-11-64
Source DB: PubMed Journal: J Neuroinflammation ISSN: 1742-2094 Impact factor: 8.322
Detailed information of myelin donors
| 2010-005 | F | 68 | 10:40 | 6.4 | MS | 57 | RR-SP | |
| 2010-045 | F | 84 | 07:35 | - | MS | 50 | PR | |
| 2010-117 | F | 60 | 10:40 | 6.48 | MS | 7 | SP | |
| 2011-008 | M | 54 | 08:15 | 6.39 | MS | 12 | PP | |
| 2011-035 | F | 50 | 07:35 | 6.45 | MS | 17 | SP | |
| 2011-048 | M | 53 | 10:00 | 6.38 | MS | 24 | SP | |
| 2011-080 | F | 56 | 08:25 | 6.16 | MS | 32 | SP | Vitamin D |
| 2011-089 | M | 64 | 07:30 | 6.49 | MS | 35 | RR-SP | |
| 2011-093 | M | 56 | 10:10 | 7.1 | MS | 13 | RR | |
| 2011-100 | F | 71 | 07:05 | 6.32 | MS | 31 | RR-SP | |
| 2011-120 | M | 73 | 08:45 | 6.4 | MS | 42 | SP | β-interferon |
| 2010-007 | F | 85 | 05:20 | 7.07 | HC | - | - | |
| 2010-062 | F | 94 | 05:50 | 7.04 | HC | - | - | |
| 2010-068 | M | 85 | 08:35 | 6.04 | HC | - | - | |
| 2010-070 | F | 60 | 07:30 | 6.8 | HC | - | - | |
| 2011-021 | F | 85 | 07:05 | - | HC | - | - | |
| 2011-039 | F | 91 | 04:15 | 6.5 | HC | - | - | |
| 2011-046 | F | 89 | 04:45 | 6.67 | HC | - | - | |
| 2011-049 | F | 83 | 04:40 | 6.04 | HC | - | - | |
| 2011-091 | M | 76 | 06:45 | 6.31 | HC | - | - | |
| 2012-048 | M | 81 | 06:40 | 6.7 | HC (depression) | - | - | |
| 2012-049 | F | 70 | 07:35 | 6.03 | HC | - | - | |
| 2012-052 | F | 64 | 05:40 | 6.35 | HC | - | - |
F/M, female/male; HC, healthy control; MS, multiple sclerosis; NBB, Netherlands Brain Bank donor number; PMD, postmortem delay; PP, primary progressive MS; RR, relapsing remitting MS; SP, secondary progressive MS.
Detailed information of microglia donors
| 2012-071 | F | 57 | 7:40 | 6.47 | HC |
| 2012-080 | M | 86 | 5:50 | 6.48 | PD |
| 2012-091 | F | 61 | 5:55 | 6.63 | PD |
| 2012-101 | M | 80 | 4:25 | 6.59 | HC |
| 2012-104 | M | 79 | 6:30 | 6.3 | HC (personality disorder) |
| 2012-113 | M | 59 | 10:45 | 6.5 | MS |
| 2013-003 | M | 60 | 5:00 | 6.2 | PD |
| 2013-008 | F | 74 | 3:45 | 6.55 | FTD |
| 2013-010 | F | 89 | 6:35 | 6.73 | HC |
| 2013-016 | M | 83 | 5:15 | 6.6 | HC |
F/M, female/male; FTD, frontotemporal dementia; HC, healthy control; MS, multiple sclerosis; NBB, Netherlands Brain Bank donor number; PD, Parkinson disease; PMD, postmortem delay.
Figure 1Quantification of myelin phagocytosis by using a pH-sensitive fluorescent dye. (A) Myelin was labeled with pHrodo and resuspended in PBS pH 7.4, 6, or 4. Fluorescent intensity was measured on a Varioskan Flash and increased in signal with decreasing pH. (B) THP-1 macrophages were incubated without (gray line) or with 12.5 μg pHrodo-labeled myelin (black line) for 6 and 24 hours, and measured with flow cytometry. Fluorescence increased over time as THP-1 macrophages phagocytosed myelin. Uptake of pHrodo-labeled myelin (red) by (C) THP-1 macrophages and by (D) primary human microglia. Microglia were stained with phalloidin (green) to visualize actin filaments. Insert shows a close-up of a phagocytosing microglia. (E) Percentage of cells that phagocytosed pHrodo-labeled myelin in (E). THP-1 macrophages and (F) primary human microglia over time measured with flow cytometry. Scale bar is 25 μm.
Figure 2Increased uptake of MS myelin by THP-1 macrophages after 6 and 24 hours. (A) Flow-cytometric analysis of live cells defined by forward and sideward scatter (FSC and SSC) characteristics and the viability dye eFluor for uptake of pHrodo-labeled myelin after 6 and 24 hours of incubation. (B). Histograms showing uptake of 11 MS and 12 control myelin samples (pHrodo signal) after 6 and 24 hours. (C) THP-1 macrophages phagocytosed MS myelin more efficiently than control myelin after 6 and 24 hours. Both the percentage of cells that took up myelin and the amount of myelin taken up (geoMFI) was significantly higher when cells were incubated with MS myelin. Shown is the mean for each myelin sample in four independent experiments. Data were analyzed with the Mann–Whitney U test. HC, healthy control; MS, multiple sclerosis. * < 0.05; ** < 0.005; *** < 0.0005.
Figure 3Increased uptake of MS myelin by primary human microglia after 24 hours. (A) Flow-cytometric analysis of live cells defined by forward and sideward scatter (FSC and SSC) characteristics and the viability dye eFluor were analyzed for uptake of pHrodo-labeled myelin after 24 hours of incubation. (B) Histograms showing uptake of 11 MS and 12 control myelin samples (pHrodo signal) after 24 hours. (C) Microglia phagocytosed MS myelin more efficiently than control myelin after 24 hours. The amount of myelin phagocytosed (geoMFI) was significantly higher when cells were incubated with MS myelin. Shown is the mean of 10 independent experiments. Data were analyzed with the Mann Whitney U test. HC, healthy control; MS, multiple sclerosis.
Comparison of phagocytosis of MS versus control myelin in the different matched subgroups
| 0.0010b | 0.012a | 0.0023b | ||
| 0.0005c | 0.0016b | 0.0082a | ||
| 0.0006b | 0.0004c | 0.0082a | ||
| 0.0001c | 0.0008b | 0.0023b | ||
| 0.4791 | 0.3884 | 0.9452 | ||
| 0.0106a | 0.0496a | 0.0734 |
GeoMFI, geomean fluorescence intensity; PMD, postmortem delay. aP < 0.05; bP < 0.005; cP < 0.0005.
Comparison in uptake of MS versus control myelin by THP-1 macrophages after 6 and 24 hours, and by primary human microglia after 24 hours, expressed as the percentage of cells that had phagocytosed myelin and as the amount of myelin taken up by the cells (geoMFI). Data were analyzed with the Mann–Whitney U test. P values are provided for of all myelin samples, as well as for age- and PMD-matched subgroups.